A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
Just because a business has cash doesn’t mean it’s a good investment. Luckily, StockStory is here to help you separate the winners from the losers. Keeping that in mind, here are two companies with net cash positions that can continue growing sustainably and one best left off your watchlist.
One Stock to Sell:
Warby Parker (WRBY)
Net Cash Position: $50.61 million (1.7% of Market Cap)
Founded in 2010, Warby Parker (NYSE: WRBY) designs, manufactures, and sells eyewear, including prescription glasses, sunglasses, and contact lenses, through its e-commerce platform and physical retail locations.
Why Does WRBY Fall Short?
- Modest revenue base of $890.6 million gives it less fixed cost leverage and fewer distribution channels than larger companies
- Poor expense management has led to operating margin losses
- Push for growth has led to negative returns on capital, signaling value destruction
At $24.68 per share, Warby Parker trades at 52.1x forward P/E. Dive into our free research report to see why there are better opportunities than WRBY.
Two Stocks to Buy:
Snowflake (SNOW)
Net Cash Position: $182.9 million (0.2% of Market Cap)
Named after the unique architecture of its data warehouse which resembles a snowflake pattern, Snowflake (NYSE: SNOW) provides a cloud-based data platform that enables organizations to consolidate, analyze, and share data across multiple cloud providers.
Why Do We Love SNOW?
- Average billings growth of 31.4% over the last year enhances its liquidity and shows there is steady demand for its products
- Market share will likely rise over the next 12 months as its expected revenue growth of 28.4% is robust
- Well-designed software integrates seamlessly with other workflows, enabling swift payback periods on marketing expenses and customer growth at scale
Snowflake is trading at $273.89 per share, or 14.4x forward price-to-sales. Is now the time to initiate a position? See for yourself in our comprehensive research report, it’s free.
DexCom (DXCM)
Net Cash Position: $1.08 billion (3.7% of Market Cap)
Founded in 1999 and receiving its first FDA approval in 2006, DexCom (NASDAQ: DXCM) develops and sells continuous glucose monitoring systems that allow people with diabetes to track their blood sugar levels without repeated finger pricks.
Why Should You Buy DXCM?
- Existing business lines can expand without risky acquisitions as its organic revenue growth averaged 12.5% over the past two years
- Free cash flow margin grew by 26 percentage points over the last five years, giving the company more chips to play with
- Improving returns on capital reflect management’s ability to monetize investments
DexCom’s stock price of $75.65 implies a valuation ratio of 28.7x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
